# US 2017/0281676 A1 · Hiv-cure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281676 A1
- Document ID: US20170281676A1
- Status: Published application
- Kind: A1
- Application number: 15/480,105
- Filed: 2017-04-05
- Published: 2017-10-05
- Earliest claimed: 2016-04-05
- Assignees: Lupus Foundation of Gainesville
- Applicants: Lupus Foundation of Gainesville
- Inventors: Eftim Josif Adhami
- Web page: https://patentgrep.com/patent/US20170281676A1

## CPC

- A61K 33/24: Heavy metals; Compounds thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/36: Arsenic; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- A61P 31/18: for HIV
- A61M 16/01: specially adapted for anaesthetising {(A61M16/104, A61M16/18 take precedence)}
- A61M 16/04: Tracheal tubes (catheters in general A61M25/00)
- A61M 16/12: by mixing different gases
- A61M 2202/0241: Anaesthetics; Analgesics
- A61M 2202/0484: Alcohol
- A61M 2205/502: User interfaces, e.g. screens or keyboards
- A61M 2230/432: partial CO2 pressure (P-CO2)
- A61M 2230/437: the anaesthetic agent concentration
- A61M 2250/00: Specially adapted for animals
- Y02C 20/10: of nitrous oxide (N2O)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02C: CAPTURE, STORAGE, SEQUESTRATION OR DISPOSAL OF GREENHOUSE GASES [GHG]

## Abstract

The embodiments use an innovative approach with the goal of permanent eradication of the virus. Instead of using drugs that block different stages of the virus life cycle (which have failed to induce a permanent cure), or approaches attempting to track infected cells, the embodiments use small virucidal molecules that are known to destroy the virus in vitro and that can easily penetrate all human cells, including memory cells or other reservoir cells. The problem with the use of small molecules is their toxicity to humans or animals when administered in doses sufficient to achieve intracellular concentrations high enough to destroy the virus in all forms. The embodiments overcome these toxicities (especially the comatose state) by using a 24-hour treatment with general anesthesia, endotracheal intubation with hemodynamic support, and controlled monitored ventilation; also, a combination of these molecules are used which decreases toxicity but has additive virucidal effects.

## Claims

### Claim 1

A method of treating systemic infectious and neoplastic diseases in humans or animals, comprising the steps:
a. as a first step, placing the human or animal subject under standard general anesthesia, with inhalation and intravenous anesthetics and endotracheal intubation;
b. monitoring continuously life functions in standard general anesthesia practice;
c. injecting or giving by inhalation, using measured rates and concentrations, one or more of chemicals with small-sized molecules from the list of ethanol, isopropyl alcohol (isopropanol), methanol, and ethylene glycol, or that destroy infectious agents or neoplastic cells in vitro, and not to be classical antibiotics, and able to easily penetrate all body fluids and cells, in order to reach and destroy these agents wherever they are, without the need for using complex methods of separating infected (or abnormal) cells with non-infected (or healthy) cells.
d. monitoring the toxicity of these chemicals to the treated subject and monitoring the disease-killing ability, by monitoring directly or indirectly the blood levels of these chemicals and the vital functions;
e. controlling the toxicity of these chemicals to the treated subject by maintaining endotracheal intubation to prevent aspiration and provide ventilation, combining these chemicals in such a way as to maximize the disease-killing effect but minimize the toxicity to the subject, or in such a way as one chemical blocks the toxicity of the other(s);
f. continuing the infusion in sufficient time to destroy the disease agent(s) wherever they are found in the body; and
g. stopping the infusions and help the subject recover from general anesthesia as a last step.

### Claim 2 (depends on 1)

The method in claim 1 wherein small virus-killing diffusible molecules can be used for permanently eradicating from the body the viruses human immunodeficiency virus, feline immunodeficiency virus, herpes viruses, ebola virus, and hepatitis c virus and other viruses.

### Claim 3 (depends on 1)

The method in claim 1 wherein small virus-killing diffusible molecules can be used to suppress the replication of the virus human immunodeficiency virus, feline immunodeficiency virus, herpes viruses, ebola virus, hepatitis c virus and other viruses, even without permanent eradication.

### Claim 4 (depends on 1)

The method in claim 1 wherein the above chemicals can be used to kill all kinds of bacteria in the body during systemic infections septicemia, sepsis, septic shock, bacterial endocarditis.

### Claim 5 (depends on 1)

The method in claim 1 wherein the above chemicals can be used to kill parasites in the body including schistosomiasis, malaria, cysticercosis, and trichinellosis.

### Claim 6 (depends on 1)

The method in claim 1 wherein the above chemicals can be used to kill cancer cells, lymphoma cells, tumors, and metastatic cells wherever they are in the body.

### Claim 7 (depends on 1)

The method in claim 1 wherein the above treatment is used as a preventive single- or multiple-session procedure to prevent metastatic spread after the original tumor or cancer has been removed or treated.

### Claim 8 (depends on 1)

The method in claim 1 wherein ethanol is the small disease-treating molecule used as an intravenous infusion.

### Claim 9 (depends on 8)

The method in claim 8 wherein isopropyl alcohol (isopropanol) is added to the infusion of ethanol, thus achieving higher combined alcohol concentrations and better disease-treating activity, without significantly increasing toxicity, with ethanol blocking the toxicity of isopropanol.

### Claim 10 (depends on 8)

The method in claim 8 wherein either methanol or ethylene glycol or a combination of those, are infused after the ethanol infusion is started, thus achieving higher combined alcohol concentrations and better disease-treating activity, without significantly increasing toxicity, with ethanol blocking the toxicity of methanol and ethylene glycol.

### Claim 11 (depends on 10)

The method in claim 10 wherein fomepizole is added as an intravenous infusion in order to block the dehydrogenase enzyme activity in addition to ethanol and thus decreasing the toxicity of methanol and/or ethylene glycol.

### Claim 12 (depends on 1)

The method in claim 1 wherein ethylene oxide gas is delivered by inhalation through a modified anesthesia machine, in order to kill viruses, bacteria and parasites.

### Claim 13 (depends on 1)

The method in claim 1 wherein a variety of combinations of concentrations of ethanol, methanol, isopropanol, ethylene glycol, and ethylene oxide, are used in such way as to increase the combined activity against infectious or neoplastic diseases, but without increasing the toxicity to the subject.

### Claim 14 (depends on 1)

The method in claim 1 wherein hexavalent or trivalent chromium is used with intravenous infusion in order to kill human immunodeficiency virus or other viruses.

### Claim 15 (depends on 2)

The method in claim 2 wherein arsenic trioxide is injected as intravenous infusion before the other infusions, in order to induce apoptosis (cell death) and thus expose the intracellular virus or viruses to the killing effects of the chemicals with small-sized molecules.

### Claim 16 (depends on 3)

The method in claim 3 wherein arsenic trioxide is injected as intravenous infusion before the other infusions, in order to induce apoptosis (cell death) and thus expose the intracellular virus or viruses to the killing effects of the chemicals with small-sized molecules.

### Claim 17 (depends on 8)

The method in claim 8 wherein ethanol is used, by intravenous infusion, near the end of pregnancy, in human-imunodeficiency-virus-infected mother (human or animal), in order to eradicate the virus in mother and fetus and prevent the child from being born infected with the virus or getting infected during delivery.

### Claim 18 (depends on 1)

The method in claim 1 wherein flumazenil is added as an intravenous infusion to reduce the depth of coma induced by alcohols and other small toxic molecules, and thus decrease the toxicity and make the subject's recovery from general anesthesia faster.

### Claim 19

An anesthesia monitoring apparatus comprising
a. an expiratory air flow tube going from the patient to the anesthesia machine;
b. a thinner connection tube sampling the air of the said expiratory air flow tube;
c. a mass spectrometer device that measures continuously the end-tidal concentrations of ethanol, methanol, isopropanol, ethylene glycol, and ethylene oxide, in addition to the commonly monitored concentrations of carbon dioxide, nitrous oxide, and sevoflurane, and receives the air from the said connection tube; and
d. a monitoring screen where the concentrations of all of the said substances are displayed live over time.

### Claim 20

An anesthesia air circuit device comprising:
a. a standard oxygen supply with meter and dial;
b. a standard nitrous oxide supply with meter and dial;
c. a common tubing that mixes the gases from the said meters and dials and sends the air mixture towards the patient;
d. a standard sevoflurane delivery device connected to the said tubing in the direction of the patient, and adding sevoflurane to the mixture;
e. an additional device connected to the said tubing in the direction of the patient, that measures and provides the desired concentrations of ethylene oxide gas to the air mixture, with the purpose of treating disease by killing infectious agents and for providing general anesthesia;
f. an ethylene oxide concentration final checking device with alarm system connected to the said tubing in the direction of the patient, with the purpose of safety; and
g. an oxygen concentration safety check device connected to the said tubing just before it connects to the endotracheal tube of the patient.
